Evaluating Carthamus Oxyacantha for 5α-Reductase Inhibition: Therapeutic Perspectives in BPH
January 2023
in “
Journal for ReAttach Therapy and Developmental Diversities
”
Studysummary In this study, the n-hexane fraction of Carthamus oxyacantha methanolic extract exhibited significant 5α-reductase inhibitory activity in vitro, suggesting potential therapeutic use for benign prostatic hyperplasia through DHT inhibition.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jrtdd.com →